Abstract: A method for treating a patient suffering from heartburn and having no substantial esophageal erosion, comprising administering to the patient a composition comprising an amount of famotidine between about 5 mg and 10 mg. In one embodiment, the amount of famotidine is about 5 mg. In another embodiment, the amount of famotidine is about 10 mg.A method for treating a patient suffering from heartburn and having no substantial esophageal erosion, comprising administering to the patient a composition comprising an amount of famotidine between about 5 mg and 10 mg, and an antacid. In one embodiment, the amount of famotidine is about 5 mg. In another embodiment, the amount of famotidine is about 10 mg.

Abstract: Hydrolyzed gelatin has been found to provide an improvement in taste and mouthfeel when incorporated in small amounts into chewable tablets containing ingredients requiring taste masking. Medicinals and nutritional supplements may now be prepared as chewables for those who find tablets difficult to swallow, for example children and older adults, or for those who prefer the convenience. There is a particularly large improvement in the taste and mouthfeel of chewables incorporating magaldrate and/or calcium carbonate.

Abstract: Compositions for oral administration for the treatment of gastric disorders comprising histamine H.sub.2 -receptor antagonist, and antacid, optimally buffered to promote local absorption of the H.sub.2 -receptor antagonist, wherein the quantity of H.sub.2 -receptor antagonist per unit dosage form is less than 25 mg.

Abstract: Compositions for oral administration for the treatment of gastric disorders comprising histamine H.sub.2 -receptor antagonist and antacid, optionally buffered to promote local absorption of the H.sub.2 -receptor antagonist, wherein the quantity of H.sub.2 -receptor antagonist per unit dosage form is less than 25 mg.

Abstract: Biowaste treatment agents for treating biowastes in a manner which: (a) keeps noxious and toxic substances from being released from the biowaste, and (b) neutralizes such substances released during the course of stabilizing the biowaste. The treatment agents include a surfactant in an amount of from 1.0 to 99 percent of the treatment agent, a metal component in an amount from 0.5 to 85 percent of the treatment agent, the metal component including a source of zinc, or copper, or a combination of copper with aluminum or iron, and an aldehyde in an amount from 0.1 to 80 percent of the treatment agent.

Abstract: An anticoagulant for blood contains sodium hydroxide, citric acid and sodium hexametaphosphate. A method of preventing the clotting of blood using the anticoagulant also is disclosed.

Abstract: A semiconductive conjugated copolymer comprises at least two chemically different monomer units which, when existing in their individual homopolymer forms, have different semiconductor bandgaps. The proportion of said at least two chemically different monomer units in the copolymer is selected to control the semiconductor bandgap of the copolymer so as to control the optical properties of the copolymer. The copolymer is formed in a manner enabling it to be laid down as a film without substantially affecting the luminescent characteristics of the copolymer and is stable at operational temperature.The semiconductor bandgap may be spatially modulated so as to increase the quantum efficiency of the copolymer when excited to luminesce, to select the wavelength of radiation emitted during luminescence or to select the refractive index of the copolymer.

Abstract: An antacid product having extended duration of residence in the gastric and upper intestinal systems has been developed. This antacid product includes a blend of 10-70% by volume nonphospholipid lipid vesicles, with a particulate base. An antiflatulence agent may also be included. A method of providing extended duration amelioration of acid build up in the gastric and upper intestinal tract using this product is also disclosed.

Abstract: This invention is an antacid composition capable of forming a floating gelatinous mass when contacted with aqueous acid and consisting essentially of, as active ingredients, xanthan gum; an effective acid neutralizing amount of hexitol stabilized aluminum hydroxide and a gas producing material capable of producing a non-toxic gas when contacted with aqueous acid which may be formulated as a solid, powder, tablet or suspension.

Abstract: Biowaste treatment agents for treating biowastes in a manner which: (a) keeps noxious and toxic substances from being released from the biowaste, and (b) neutralizes such substances released during the course of stabilizing the biowaste. The treatment agents include a surfactant in an amount of from 1.0 to 99 percent of the treatment agent, a metal component in an amount from 0.5 to 85 percent of the treatment agent, the metal component including a source of zinc, or copper, or a combination of copper with aluminum or iron, and an aldehyde in an amount from 0.1 to 80 percent of the treatment agent.

Abstract: A biconvex tablet whose height and diameter are approximately equal and are from 1.5 to 4 mm and which, besides conventional pharmaceutical auxiliaries, contains an antacid as active substance is described.

Abstract: This invention relates to a pharmaceutical composition for use in the treatment of pain and inflammation and the treatment of acid indigestion, sour stomach, heartburn and symptoms of upset stomach associated with these conditions in a mammalian organism, said composition comprising:(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen;(ii) an amount effective in the treatment of acid indigestion, sour stomach and/or heartburn of at least one of the antacids; and(iii) optionally, an amount effective in treating excess gas and flatulence of an anti-gas agent.

Abstract: Pharmaceutical medications and methods are disclosed for providing instant and sustained relief from pain or symptoms associated with episodic heartburn in humans. The medications consist essentially of antacids and histamine H.sub.2 -receptor antagonists, and may be administered on an as-needed basis in liquid or solid dosage forms. Typical antacids which may be used in combination with the histamine H.sub.2 -receptor antagonist are conventional antacids which are well known and widely used in the treatment of excess acid related gastrointestinal dysfunctions. Exemplary of typical antacids include, sodium bicarbonate, calcium carbonate, magnesium hydroxide and aluminum hydroxide, as well as commercially available high potency, flavored antacids. Histamine H.sub.2 -receptor antagonists which may be used in combination include those conventionally used in the treatment of peptic ulcers, such as, for example, cimetidine, ranitidine, famotidine and nizatidine.

Abstract: The present invention relates to an antacid preparation having a prolonged gastric residence time, comprising an antacid active substance, calcium polycarbophil and a water-insoluble, anionic polymer.

Abstract: A pharmaceutical composition is provided for the protection of the oesogastroduodenal mucous membrane, which composition has an active antacid component comprising sufficient guar gum to provide antacid and buffering effect at a pH of from 0.8 to 3.5, and at least one antacid agent other than guar gum in an amount effective as an antacid.

Abstract: A process for the preparation of a viscosity-stable antacid composition containing an alginic acid salt comprising reacting an antacid material with said salt at elevated temperatures to form a reaction product and recovering said reaction product in stabilized form.

Abstract: The invention relates to a new pharmaceutical preparation of high acid-binding capacity, of delayed effect, of increased bioavailability for neutralization of gastric acid and optionally to other pharmaceutical preparations acting in the gastrointestinal tract, first of all of laxative effect by mixing 100 parts by mass of a powdered basic magnesium compound or the powdered mixture of basic magnesium compounds and basic aluminium compounds with 2-2500 parts of a dry or swollen organic acid of polymeric character and therapeutically acceptable, e.g. cellulose-glycolic acid, starch-glycolic acid or polymer acrylic and/or methacrylic acid, letting this powdered mixture to stand for 1-24 hours at the temperature of 20.degree.-80.degree. C.

Abstract: Discosed are (i) a boehmite-type aluminum hydroxide which is represented by the formulaAlO(OH).xSO.sub.4.nH.sub.2 Owherein 0.01<.times.<0.10 and 0.ltoreq.n<1; and (ii) a process for preparing a boehmite-type aluminum hydroxide represented by the formulaAlO(OH).xSO.sub.4.nH.sub.2 Owherein 0.01<.times.<0.10 and 0.ltoreq.n<1, the process comprising surface-treating a boehmite-type aluminum hydroxide with sulfuric acid or a sulfate capable of forming sulfuric acid by heating or by hydrolysis, the boehmite-type aluminum hydroxide to be treated being represented by the formulaAlO(OH).mH.sub.2 Owherein 0.ltoreq.m<1.

Abstract: A mouth cleansing composition for removing dried secretion deposits in and around a user's oral cavity is disclosed. The composition is a mixture of an aqueous salt containing solution, glycerin, hydrogen peroxide, and an acid neutralizing agent.

Abstract: Orally ingestible liquid compositions for suspending therein orally administrable pharmaceutically active compositions comprising triglycerides, propylene glycol ester, or monoacetylated glycerides of medium chain length alkanoic acids, polyglycerol esters, and colloidal silicon dioxide.

Abstract: An oral phosphate ion-adsorbing agent containing as an effective component a boehmite-type aluminum hydroxide which is represented by the formulaAlO(OH).multidot.nH.sub.2 Owherein 0.ltoreq.n<1 and which is about 0.2 to about 1.0 meq/g in the amount of active OH group present on the surface thereof and at least about 200 m.sup.2 /g in the BET specific surface area.

Abstract: A method is disclosed for reducing the propensity of a dairy cow to develop severe milk fever upon calving comprising administering thereto a composition comprising a water-soluble calcium compound and a complexing agent for serum phosphorus.

Abstract: The invention relates to the production of a new pharmaceutical preparation of high acid-binding capacity, of delayed effect, of increased bioavailability for neutralization of gastric acid and eventually to other pharmaceutical preparations acting in the gastrointestinal tract, first of all of laxative effect by mixing 100 parts by mass of a powdered basic magnesium compound or the powdered mixture of basic magnesium compounds and basic aluminum compounds with 2-2500 parts of a dry or water-swollen organic acid of polymeric character and therapeutically acceptable, e.g. cellulose-glycolic acid, starch-glycolic acid or polymer acrylic and/or methacrylic acid, letting this powdered mixture to stand for 1-24 hours at the temperature of 20.degree.-80.degree. C.

Abstract: A process for the preparation of an antacid material prepared from magnesium aluminum hydroxide, wherein magnesium hydroxide and/or magnesium oxide is reacted in an atomic ratio of magnesium to aluminum of 1:1 to 3:1 with an aqueous solution of aluminum sulfate until the pH of the reaction mixture is from 4.0 to 8.0, whereafter water-soluble components are removed from the mixture is known manner and this is isolated and, if desired, dried is described as well as a new embodiment of the formula [Mg.sub.5 Al.sub.10 (OH).sub.26 O.sub.5 ](SO.sub.4).sub.2 .multidot.nH.sub.2 O. Also described are pharmaceutical compositions containing such antacid material, in admixture with a conventional pharmaceutical adjuvant, and a method of combating hyperacidity and gastrointestinal diseases, which comprises administering such antacid material.

Abstract: A pharmaceutical composition including magnesium alginate and an antacid material useful in the treatment of reflux esophagitis.

Abstract: There are provided pharmaceutical dosage forms for oral administration comprising a gelatin capsule encapsulating an admixture of at least one solid hygroscopic medicinal substance, which would otherwise disturb the gastric tract balance, with an at least partially hydrogenated and/or solidified vegetable oil.

Abstract: A pharmaceutical composition suitable for oral adminstration comprising particulate cimetidine suspended in an aqueous phase containing a buffer which maintains the pH at greater than 7 and a suspending agent.

Abstract: There are provided gastric cytoprotective exogenously acidified aluminum hydroxide antacid compositions which are formed by acidifying, for example, commercial liquid antacid suspensions containing aluminum hydroxide, antacid powders or solids containing aluminum hydroxide, or aluminum hydroxide gel, to the point where the aluminum hydroxide is solubilized. The solutuions may be formulated into liquid dosage forms or spray dried and formulated into solid dosage forms.

Abstract: Decubitus ulcers are treated with a preconditioning aqueous medium and then with a non-systemic basic ointment. The aqueous medium comprises an aqueous solution of pyridoxine hydrochloride, zinc chloride, dextrose, ethanol and sodium chloride, with a trace of phenyl mercuric nitrate N.F., and has a pH in the range of 4.3 to 6.8 so as to facilitate ionization of naturally occurring amino acids at the wound site. The ointment comprises calcium carbonate, magnesium hydroxide, aluminum hydroxide, zinc chloride, sodium chloride, anhydrous lanolin, hydrophilic ointment and vitamin A and has a pH in the range of from about 6.5 to 9.0 so as to facilitate chelation of the amino acid and zinc ions and enhance tissue repair.

Abstract: The present invention relates to the aluminum hydroxide having a specific surface area of at least 350 m.sup.2, preferably at least 400 m.sup.2, per g. and to a process for its preparation. The aluminum hydroxide should be capable of absorbing at least 1 g of fat per g. of material. The aluminum hydroxide is preferably part of a pharmaceutical preparation.